ANPEP and neoplasm: Since HLA mutations were unlikely to be a primary reason for progression on ICB, we next assessed whether epigenetic silencing of HLA and APM genes, a known mechanism for tumor immune evasion in HNSCC (14, 15), could be reversed with low-dose 5-aza treatment.